PRESS RELEASES & ARTICLES
STAY UPDATED

Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections

February 15, 2018

Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drugresistant bacterial infections, announces today that the U.S Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate AAI101 when given in fixed dose combination with the antibiotic cefepime, a powerful treatment for serious hospital-acquired Infections.

PDF

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

January 25, 2018

Topas Therapeutics GmbH (Topas), today announced that it will serve as the exclusive translational partner for the recently extended Collaborative Research Center (CRC) 841, “Liver inflammation: infection, immune regulation and consequences.” CRC 841 has 25 sub-projects investigating the causes and mechanisms of inflammatory liver diseases, laying the groundwork for new therapeutic approaches.

PDF

Immatics Proprietary Target Selected for the Development of Cancer Immunotherapies

December 21, 2017

Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option under the existing discovery, development and commercialization agreement between the companies to exclusively license from Immatics a proprietary immunotherapy target for further development and commercialization in oncology.

PDF

Immatics Appoints Thomas Ulmer as CFO

December 19, 2017
PDF

Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

December 19, 2017
PDF

Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2

December 08, 2017
PDF

Allecra Therapeutics Announces New Staged Financing Deal

December 04, 2017
PDF

Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017

November 30, 2017
PDF

Arsanis Announces Closing of Initial Public Offering

November 20, 2017
PDF

Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

November 13, 2017
PDF

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

November 02, 2017
PDF

Topas Therapeutics Appoints Rupert Sandbrink as CDO and CMO

October 26, 2017
PDF

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

October 04, 2017
PDF

Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine®

September 28, 2017
PDF

Allecra Announces Initiation of a Phase 2 Clinical Trial

September 07, 2017
PDF

Immatics Initiates a Phase I trial using ACTolog

August 22, 2017
PDF

Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards

June 16, 2017
PDF

EMBL Ventures portfolio company Luxendo acquired by Bruker

May 08, 2017
PDF

Arsanis Completes $45.5 Million Series D Financing

April 26, 2017
PDF

Paul Sekhri joins Topas Therapeutics as Chairman of the Board

April 04, 2017
PDF

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

April 04, 2017
PDF

Arsanis and Adimab Enter Into License Agreement

February 27, 2017
PDF

Arsanis Announces First Patient Dosed in Global Phase 2 Study

January 24, 2017
PDF

Crescendo partners with Genedata

January 10, 2017
PDF

Luxendo announces Series A extension

January 09, 2017
PDF

Opsona announces preliminary MDS results

December 20, 2016
PDF

Opsona receives orphan designation

October 25, 2016
PDF

Crescendo enters a collaboration with Takeda

October 10, 2016
PDF

ViraT enters collaboration with Boehringer Ingelheim

September 28, 2016
PDF

Crescendo strengthens IP portfolio

September 27, 2016
PDF

Topas Series A Financing

March 22, 2016
PDF
© EMBL Ventures 2018